Advisory report from the Health Council of the Netherlands to include Human papillomavirus vaccination in the National Immunisation Programme for the prevention of cervical cancer;Advies van de Gezondheidsraad om vaccinatie tegen Humaan papillomavirus op te nemen in het Rijksvaccinatieprogramma om baarmoederhalskanker te voorkomen

Nederlands Tijdschrift voor Geneeskunde

Volumn 152, Issue 17, 2008, Pages 981-983

  Boeke, A J P ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

CANCER PREVENTION; CANCER SCREENING; CLINICAL EFFECTIVENESS; CONDYLOMA ACUMINATUM; DRUG SAFETY; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INFECTION RISK; NETHERLANDS; NOTE; PATIENT MONITORING; PATIENT PARTICIPATION; PRACTICE GUIDELINE; PREVENTIVE HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; SOCIOECONOMICS; TREATMENT RESPONSE; UTERINE CERVIX CANCER; VACCINATION;

ADOLESCENT; CHILD; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PUBLIC HEALTH; SAFETY; UTERINE CERVICAL NEOPLASMS;

EID: 44949221091     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (14)

1. Vaccinatie tegen baarmoederhalskanker. Publicatienr 2008/08. Den Haag: Gezondheidsraad; 2008.
2. Wiersma T. Standpunt NHG over HPV-vaccinatie. Verzoeken om HPV-vaccinatie in afwachting van advies van de Gezondheidsraad vooralsnog terughoudend benaderen. Huisarts Wet. 2007;50:167-8.
3. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-9.
4. Winer RL, Koutsky L. Genital human papillomavirus infection. In: Holmes KK, Sparling FP, Stamm EW, Piot P, Wasserheit JN, Corey L, et al, editors. Sexually transmitted diseases. 4th rev ed. New York: McGraw-Hill; 2007. p. 489-508.
5. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. N Engl J Med. 2007;356:1928-43.
6. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915-27.
7. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. HPV PATRICIA Study Group. Lancet. 2007;369:2161-70.
8. Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Future II Study Group. Lancet. 2007;369:1861-8.
9. Coupé VMH, Berkhof J, Bulkmans NWJ, Snijders PJF, Meijer CJLM. Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer. 2008;98:646-51.
10. Kjaer SK, Tran TN, Sparen P, Tryggvadottir L, Munk C, Dasbach E, et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis. 2007;196:1447-54.
11. Boot HJ. Objectieve registratie en interpretatie van vaccinbijwerkingen: een essentieel element van vaccinatie. Ned Tijdschr Geneeskd. 2007;151:2707-8.
12. Bulkmans NW, Berkhof J, Rozendaal L, Kemenade FJ van, Boeke AJ, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007;370:1764-72.
13. Bais AG, Kemenade FJ van, Berkhof J, Verheijen RH, Snijders PJ, Voorhorst F, et al. Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs. Int J Cancer. 2007;120:1505-10.
14. Zimet GD, Liddon N, Rosenthal SL, Lazcano-Ponce E, Allen B. Chapter 24: psychosocial aspects of vaccine acceptability. Vaccine. 2006;24 Suppl 3:S201-9.